- Home
- BTGO vs KALV Comparison
BTGO vs KALV Comparison
Compare BTGO & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTGO | KALV |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | 603 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 961.8M | 1.0B |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | BTGO | KALV |
|---|---|---|
| Price | $12.39 | $26.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | $14.83 | ★ $32.60 |
| AVG Volume (30 Days) | 470.7K | ★ 4.1M |
| Earning Date | 05-13-2026 | 07-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000,000.00 |
| Revenue This Year | N/A | $185.42 |
| Revenue Next Year | $34.41 | $59.23 |
| P/E Ratio | $10.81 | ★ N/A |
| Revenue Growth | N/A | ★ 495.66 |
| 52 Week Low | $7.25 | $9.83 |
| 52 Week High | $15.30 | $26.85 |
Technical Indicators
Market Signals| Indicator | BTGO | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 64.35 | 75.25 |
| Support Level | $9.62 | $14.66 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.71 | 0.57 |
| MACD | 0.17 | 0.45 |
| Stochastic Oscillator | 95.46 | 98.41 |
Price Performance
Historical ComparisonAbout BTGO BitGo Holdings Inc. Class A Common Stock
BitGo Holdings Inc provides various offerings to its clients including multi-signature blockchain wallet solutions allowing for secure storage, trade settlement, staking solutions, and lending of digital assets. The Company also provides professional services to develop smart contracts. Its clients range from crypto-native companies that use its self-custody wallet technology to traditional financial services firms that leverage its licensed custody, staking and trading capabilities within their own products and services.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.